成人起病自身免疫性糖尿病:GAD抗体阳性患者的非胰岛素依赖状态预测
日本八中心回顾性队列分析345例符合SPIDDM诊断标准的GAD抗体阳性患者,中位随访3.0年,162例启动胰岛素治疗,183例未启动。Cox模型显示BMI、HbA1c和GADAb水平是进展至胰岛素治疗的独立因素。同时具备BMI≥22 kg/m2、HbA1c<75 mmol/mol(9.0%)和GADAb<10.0 U/ml三因素者,86.0%在4年内无需胰岛素治疗。
要点
- BMI≥22 kg/m2、HbA1c<9.0%且GADAb<10.0 U/ml可预测至少数年非胰岛素依赖状态。
- 非胰岛素治疗组更多为男性、起病更晚、病程更短、BMI和血压更高、HbA1c和GADAb更低。
- BMI、HbA1c和GADAb水平是进展至胰岛素治疗的独立预测因素。
核心结论
- 较高BMI(≥22 kg/m2)、较低HbA1c(<75 mmol/mol[9.0%])和较低GADAb水平(<10.0 U/ml)可预测日本GAD抗体阳性糖尿病患者至少数年处于非胰岛素依赖状态。
研究设计与样本
- 回顾性队列研究,调查日本八家医疗中心电子病历中所有GAD抗体阳性患者,筛选符合SPIDDM诊断标准者进行分析。
- 共分析345例患者,随访期间162例启动胰岛素治疗(胰岛素治疗组),183例未启动(非胰岛素治疗组),中位随访3.0年。
主要发现
- 非胰岛素治疗组相比胰岛素治疗组,更可能为男性,起病年龄更晚,糖尿病病程更短,BMI更高,血压水平更高,HbA1c更低,GADAb水平更低,且降糖药物使用更少(首次GADAb阳性时)。
- Cox比例风险模型显示BMI、HbA1c水平和GADAb水平是进展至胰岛素治疗的独立因素。
- Kaplan-Meier分析显示,同时具备BMI≥22 kg/m2、HbA1c<75 mmol/mol(9.0%)和GADAb<10.0 U/ml三因素的GAD抗体阳性糖尿病患者中,86.0%在4年内无需胰岛素治疗。
关键数值与推荐
- 非胰岛素依赖状态的预测因素:BMI≥22 kg/m2、HbA1c<75 mmol/mol(9.0%)、GADAb<10.0 U/ml。
- 同时具备上述三因素者,4年内无需胰岛素治疗的比例为86.0%。
临床怎么用
- 对GAD抗体阳性的成人糖尿病患者,可结合BMI、HbA1c和GADAb水平评估短期进展至胰岛素治疗的风险。
- 同时具备BMI≥22 kg/m2、HbA1c<9.0%和GADAb<10.0 U/ml者,可预期至少数年非胰岛素依赖,但仍需随访监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Patients with GAD antibodies (GADAb) showing clinical features of type 2 diabetes typically exhibit progression to an insulin-dependent state in several months or years. This condition is diagnosed as slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM) or latent autoimmune diabetes in adults, a subtype of adult-onset autoimmune diabetes. However, some patients diagnosed with adult-onset autoimmune diabetes do not progress to an insulin-dependent state. We conducted a retrospective cohort study to identify patients with non-insulin-dependent diabetes among those diagnosed with adult-onset autoimmune diabetes using measurable indicators in routine clinical practice. METHODS: We surveyed data from the electronic medical records of all patients with GADAb from eight medical centres in Japan for selecting and analysing patients who matched the diagnostic criteria of SPIDDM. RESULTS: Overall, 345 patients were analysed; of these, 162 initiated insulin therapy (insulin therapy group), whereas 183 did not (non-insulin therapy group) during the follow-up period (median 3.0 years). Patients in the non-insulin therapy group were more likely to be male and presented a later diabetes onset, shorter duration of diabetes, higher BMI, higher blood pressure levels, lower HbA1c levels, lower GADAb levels and lesser antidiabetic agent use than those in the insulin therapy group when GADAb was first identified as positive. A Cox proportional hazards model showed that BMI, HbA1c levels and GADAb levels were independent factors for progression to insulin therapy. Kaplan-Meier analyses revealed that 86.0% of the patients with diabetes having GADAb who presented all three factors (BMI ≥ 22 kg/m2, HbA1c < 75 mmol/mol [9.0%] and GADAb <10.0 U/ml) did not require insulin therapy for 4 years. CONCLUSIONS/INTERPRETATION: Higher BMI (≥22 kg/m2), lower HbA1c (<75 mmol/mol [9.0%]) and lower GADAb levels (<10.0 U/ml) can predict a non-insulin-dependent state for at least several years in Japanese patients with diabetes having GADAb.
引用
- Wada E, Onoue T, Kinoshita T, et al. Adult-onset autoimmune diabetes identified by glutamic acid decarboxylase autoantibodies: a retrospective cohort study. Diabetologia. 2021. PMID: 34268631. doi:10.1007/s00125-021-05516-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。